Monthly or Weekly Supplementation with Cholecalciferol 20,000 IU in People Living with HIV: Results from a Nested Cohort Study
Table 2
Results of the univariate and multivariate regression analysis on the association between a 25(OH)D serum level of ≥30 ng/mL and supplementation after 12 months.
Univariate
Multivariate
OR (95% CI)
p value
OR (95% CI)
p value
Weekly dose of supplementation
3.0 (1.3–7.0)
0.012
2.7 (1.1–6.4)
0.029
Gender (male)
1.2 (0.5–2.9)
0.672
Age
1.0 (0.9–1.1)
0.284
Ethnicity (African)
0.6 (0.2–1.9)
0.400
Baseline 25(OH)D (<15 ng/mL)
0.3 (0.1–0.6)
0.002
0.3 (0.1–0.7)
0.006
Baseline Viral load (<200/mL)
2.0 (0.7–5.5)
0.174
Baseline CD4 cell count (<350/μL)
0.5 (0.2–1.3)
0.131
CD4 nadir < 200 cells/μL
0.7 (0.3-1.5)
0.390
HIV risk group: MSM
1.0 (0.5-2.0)
0.934
Time since diagnosis (years)
1.0 (0.9-1.1)
0.317
Use of tenofovir disoproxil fumarate (TDF)
0.6 (0.3–1.3)
0.171
Use of efavirenz (EFV)
0.5 (0.2–1.3)
0.131
Use of boosted protease inhibitor (PI)
1.6 (0.8–3.3)
0.224
cART including at least two of the following: TDF, EFV, boosted PI
